Who
Neil Kumar
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, BridgeBio Pharma; Director, BridgeBio Oncology Therapeutics; Director, Maze Therapeutics; Chief Executive Officer, Eidos Therapeutics.
In numbers
- Trades disclosed
- 523
- Buys
- 8
- Sells
- 74
- Bought
- $116.2M
- Sold
- $191.8M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 22 Jun 2018
- Last trade
- 17 Sep 2026
- Last filed
- 21 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Sep 2026filed 21 Sep 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $602K8,721 at $69.01 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $89K1,279 at $69.57 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $602K8,721 at $69.01 | filing |
| 17 Sep 2026filed 21 Sep 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $89K1,279 at $69.57 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $679K8,100 at $83.86 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $152K1,800 at $84.69 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $8,565100 at $85.65 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $679K8,100 at $83.86 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $152K1,800 at $84.69 | filing |
| 19 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $8,565100 at $85.65 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $154K1,900 at $81.15 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.4M17,279 at $82.21 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.2M14,602 at $82.99 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $100K1,199 at $83.77 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $154K1,900 at $81.15 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.4M17,279 at $82.21 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $1.2M14,602 at $82.99 | filing |
| 18 Aug 2026filed 20 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $100K1,199 at $83.77 | filing |
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | —33,544 | filing |
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | —19,599 | filing |
The newest 500 lines are listed; the numbers count every line.
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Neil Kumar; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.